debt_leverage_profile
Net debt ~$1.1B post-Hu-Friedy acquisition; Net Debt/EBITDA ~4.5x; 20% rate rise adds ~$22M annual interest on floating-rate tranche
Inferred
Agent_Inference
interest_rate_sensitivity
Approximately 60% fixed-rate debt; 20% rate increase on floating portion (~$400M) adds ~$16–22M annual interest expense, compressing EBITDA margin ~150bps
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
Single-use endoscopy consumables sourced from Asia (China/South Korea manufacturing); sterilization chemical inputs dependent on Gulf Coast chemical corridors
Inferred
Agent_Inference
international_expansion_readiness
Top-3 international markets: Canada (CAD), EU (EUR), Australia (AUD); EUR/USD and AUD/USD volatility poses ~5–8% revenue translation risk annually
Inferred
Agent_Inference
geographic_footprint
~35% revenue international; Canada (~15%), Europe (~12%), Rest of World (~8%); EUR and CAD devaluation most material given revenue concentration
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Medivators (now Cantel brand) proprietary chemistry for reprocessing systems creates near-captive consumable supply; single-source risk moderate-to-high for key chemistries
Inferred
Agent_Inference
business_model_type_primary
Medical device manufacturer and infection prevention solutions provider; not primarily cloud-dependent; on-premise hardware with recurring consumable pull-through
Inferred
Agent_Inference
business_model_type_secondary
Cloud termination risk minimal; Cantel operates device/consumable model with internal ERP; no mission-critical public cloud single-vendor dependency identified
Inferred
Agent_Inference
switching_cost_profile
Low API coupling risk; business model is hardware+consumable, not software API-dependent; switching costs driven by installed base lock-in and regulatory clearance cycles
Inferred
Agent_Inference
howey_test_risk_index
Primary revenue is product sales (medical devices, consumables, services); no investment-contract characteristics; Howey Test risk effectively zero
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited GDPR/CCPA exposure; Cantel handles minimal patient PII; primary data risk is employee/HCP data; compliance cost low relative to peers (~$1–3M annually)
Inferred
Agent_Inference
antitrust_exposure_flag
Moderate; endoscope reprocessing market is concentrated (Cantel/Olympus/Steris); bundling of equipment+consumables may attract scrutiny but no active DOJ/FTC action known
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~55–60% recurring (consumables, service contracts, reagents); ~40–45% transactional (capital equipment sales); strong razor/blade pull-through dynamic
Inferred
Agent_Inference
monetization_vector
Razor/blade model: proprietary reprocessing equipment drives high-margin recurring consumable and chemistry revenue; aftermarket services add annuity layer
Inferred
Agent_Inference
pricing_architecture
Cost-plus with value-based premium for infection prevention efficacy; GPO contract pricing caps upside; consumable pricing relatively sticky due to regulatory lock-in
Inferred
Agent_Inference
pricing_power_rating
Moderate-high (7/10); infection prevention is non-discretionary in hospitals; GPO contracts limit spot pricing power but provide volume stability
Inferred
Agent_Inference
target_gross_margin_bracket
Gross margin ~45–50%; consumables segment ~55–60% GM; capital equipment ~35–40% GM; blended compressed by product mix and integration costs
Inferred
Agent_Inference
churn_vulnerability_index
Minimal free-rider risk; proprietary chemistry tied to equipment via validation requirements; third-party chemistry use voids device warranty, limiting leakage
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth is sublinear to headcount; consumable volume scales through distribution without proportional headcount addition; service technician base is the binding constraint
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of incremental consumable revenue is low (~20–25% COGS); capital equipment growth requires incremental field sales/service headcount; overall sublinear scaling
Inferred
Agent_Inference
franchise_compliance_risk
null
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale: CAC likely rises as hospital system consolidation reduces buyer count; LTV/CAC ratio strong (~8–12x) given consumable annuity; GPO dependency increases
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; indirect effects via installed base creating ecosystem lock-in; not a platform model; durability relies on switching costs not network density
Inferred
Agent_Inference
asset_efficiency_ratio
AI displacement risk low; core value is physical reprocessing hardware and chemistry validation; AI could optimize service scheduling but not displace core product
Inferred
Agent_Inference
recession_resistance_tier
Tier 1 recession-resistant; infection prevention in endoscopy is procedure-linked and regulatory-mandated; elective procedure volume dips but reprocessing demand remains sticky
Inferred
Agent_Inference
customer_segment_primary
Hospitals and ambulatory surgery centers (GI endoscopy departments); top accounts are large IDNs and GPO members representing ~40% of revenue
Inferred
Agent_Inference
customer_segment_secondary
Dental practices and dental clinics (via Hu-Friedy acquisition); fragmented segment with lower concentration risk but higher churn sensitivity to economic cycles
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
CapEx ~3–4% of revenue; moderate reallocation toward dental integration (Hu-Friedy) and R&D for next-gen reprocessing systems; legacy endoscopy infrastructure well-depreciated
Inferred
Agent_Inference
sec_cik
1060349
Inferred
Agent_Inference
ticker
CMD (acquired by STERIS plc in June 2021; no longer independently traded; was NYSE:CMD; regulatory + commodity cost interaction compressed EBITDA ~200bps pre-acquisition)
Inferred
Agent_Inference